PHASE-2 STUDY OF CIS-DICHLORODIAMMINEPLATINUM(II) (NSC-119875) IN ADVANCED ADENOCARCINOMA OF OVARY

  • 1 January 1976
    • journal article
    • research article
    • Vol. 60  (1) , 55-60
Abstract
Cis-dichlorodiammineplatinum(II) was used in the treatment of 34 patients with advanced adenocarcinoma of the ovary who were resistant to conventional chemotherapy. Two dose schedules were explored: a high-dose schedule with 30 mg/m2 given daily on 3 successive days every 4 wk and a low-dose schedule with 30 mg/m2 given once every 2-3 wk. Nine patients (26.5%) showed a therapeutic response with a median duration of 6 mo. (range, 3-15 mo.). The main toxic effects included myelosuppression, renal function impairment and nausea and vomiting. The high-dose schedule proved to be more toxic without any therapeutic advantage.

This publication has 0 references indexed in Scilit: